Identification

Name
Propafenone
Accession Number
DB01182  (APRD00261)
Type
Small Molecule
Groups
Approved
Description

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. [PubChem]

Structure
Thumb
Synonyms
  • 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone
  • 2-(2'-Hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenone
  • Propafenona
  • Propafenonum
Product Ingredients
IngredientUNIICASInChI Key
Propafenone hydrochloride33XCH0HOCD34183-22-7XWIHRGFIPXWGEF-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PropafenoneTablet300 mgOralSanis Health Inc2010-02-16Not applicableCanada
PropafenoneTablet150 mgOralSanis Health Inc2010-02-16Not applicableCanada
Propafenone-150Tablet150 mgOralPro Doc Limitee2008-03-072016-07-18Canada
Propafenone-300Tablet300 mgOralPro Doc Limitee2009-05-262016-07-18Canada
RythmolTablet, film coated225 mg/1OralGlaxosmithkline Inc2010-01-042017-05-31Us
RythmolTablet, film coated150 mg/1OralGlaxosmithkline Inc2010-01-042017-05-31Us00173 0792 20 nlmimage10 8618c366
RythmolTablet150 mgOralBgp Pharma Ulc1988-12-31Not applicableCanada
RythmolTablet300 mgOralBgp Pharma Ulc1988-12-31Not applicableCanada
Rythmol SRCapsule, extended release225 mg/1OralGlaxosmithkline Inc2011-03-17Not applicableUs
Rythmol SRCapsule, extended release425 mg/1OralGlaxosmithkline Inc2011-03-17Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-propafenoneTablet300 mgOralApotex Corporation2001-02-22Not applicableCanada
Apo-propafenoneTablet150 mgOralApotex Corporation2001-02-22Not applicableCanada
Myl-propafenoneTablet300 mgOralMylan Pharmaceuticals2002-03-08Not applicableCanada
Myl-propafenoneTablet150 mgOralMylan Pharmaceuticals2002-03-08Not applicableCanada
Mylan-propafenoneTablet300 mgOralMylan Pharmaceuticals2017-10-31Not applicableCanada
Mylan-propafenoneTablet150 mgOralMylan Pharmaceuticals2017-10-31Not applicableCanada
Nu-propafenoneTablet150 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-propafenoneTablet300 mgOralPharmascience Inc2008-02-22Not applicableCanada
PMS-propafenoneTablet150 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-propafenoneTablet150 mgOralPharmascience Inc2008-02-22Not applicableCanada
Categories
UNII
68IQX3T69U
CAS number
54063-53-5
Weight
Average: 341.444
Monoisotopic: 341.199093735
Chemical Formula
C21H27NO3
InChI Key
JWHAUXFOSRPERK-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
IUPAC Name
1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one
SMILES
CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1

Pharmacology

Indication

Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.

Associated Conditions
Pharmacodynamics

Propafenone is a Class 1C antiarrhythmic drug with local anesthetic effects, and a direct stabilizing action on myocardial membranes. It is used in the treatment of atrial and ventricular arrhythmias. It works by slowing the influx of sodium ions into the cardiac muscle cells, causing a decrease in excitablity of the cells. Propafenone has local anesthetic activity approximately equal to procaine.

Mechanism of action

The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.

TargetActionsOrganism
ASodium channel protein type 5 subunit alpha
inhibitor
Human
APotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UBeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
Absorption

Nearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).

Volume of distribution
  • 252 L
Protein binding

97%

Metabolism

Metabolized primarily in the liver where it is rapidly and extensively metabolized to two active metabolites, 5-hydroxypropafenone and N-depropylpropafenone. These metabolites have antiarrhythmic activity comparable to propafenone but are present in concentrations less than 25% of propafenone concentrations.

Route of elimination

Approximately 50% of propafenone metabolites are excreted in the urine following administration of immediate release tablets.

Half life

2-10 hours

Clearance
Not Available
Toxicity

Symptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*9Not Available2615-2617delAAGADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*10Not Available100C>T / 1661G>C  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*14BNot Available1758G>AADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*17Not Available1023C>T / 2850C>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*18Not Available4133dupGTGCCCACTADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*29Not Available1659G>A / 1661G>C  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*41Not Available2988G>AADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*49Not Available100C>T / -1426C>T  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*50Not Available1720A>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*54Not Available100C>T / 1039C>T  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*55Not Available1661G>C / 2850C>T  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*59Not Available1661G>C / 2291G>A  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 2D6CYP2D6*72Not Available-1426C>T / -1235A>G  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*20Not Available1461_1462insAADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*26Not Available802C>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*8Not Available13908G>AADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*11Not Available1088C>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*12Not Available1117C>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*13Not Available1247C>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*16ANot Available554C>GADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*16BNot Available554C>GADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 3A4CYP3A4*17Not Available566T>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*6Not Available5090C>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*1CNot Available-3860G>AADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*1KNot Available-739T>G / -729C>T  … show all ADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*3Not Available2116G>A / 5347T>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*4Not Available2499A>TADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*7Not Available3533G>AADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*8Not Available5166G>A / 5347T>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*11Not Available558C>AADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*15Not Available125C>G / 5347T>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details
Cytochrome P450 1A2CYP1A2*16Not Available2473G>A / 5347T>CADR InferredPoor drug metabolizer, increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Propafenone.Experimental
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Propafenone.Experimental, Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Propafenone.Experimental
3-isobutyl-1-methyl-7H-xanthineThe serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Propafenone.Experimental
4-hydroxycoumarinThe serum concentration of 4-hydroxycoumarin can be increased when it is combined with Propafenone.Experimental
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Propafenone.Experimental, Illicit
6-O-benzylguanineThe serum concentration of 6-O-benzylguanine can be increased when it is combined with Propafenone.Investigational
7-DeazaguanineThe serum concentration of 7-Deazaguanine can be increased when it is combined with Propafenone.Experimental
7,9-DimethylguanineThe serum concentration of 7,9-Dimethylguanine can be increased when it is combined with Propafenone.Experimental
8-azaguanineThe serum concentration of 8-azaguanine can be increased when it is combined with Propafenone.Experimental
8-chlorotheophyllineThe serum concentration of 8-chlorotheophylline can be increased when it is combined with Propafenone.Approved
9-DeazaguanineThe serum concentration of 9-Deazaguanine can be increased when it is combined with Propafenone.Experimental
9-MethylguanineThe serum concentration of 9-Methylguanine can be increased when it is combined with Propafenone.Experimental
AbediterolThe therapeutic efficacy of Abediterol can be decreased when used in combination with Propafenone.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Propafenone.Approved, Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Abexinostat.Investigational
AbirateroneThe serum concentration of Propafenone can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Propafenone is combined with Acebutolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Propafenone.Approved, Investigational
AcefyllineThe serum concentration of Acefylline can be increased when it is combined with Propafenone.Experimental
AcemetacinAcemetacin may decrease the antihypertensive activities of Propafenone.Approved, Experimental, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Propafenone.Approved, Investigational
AcepromazineThe serum concentration of Propafenone can be increased when it is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe serum concentration of Propafenone can be increased when it is combined with Aceprometazine.Approved
AcetohexamidePropafenone may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetophenazineThe serum concentration of Propafenone can be increased when it is combined with Acetophenazine.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Propafenone is combined with Acetylcholine.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Propafenone.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Propafenone.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Propafenone.Approved, Vet Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Propafenone.Approved
AcyclovirThe serum concentration of Acyclovir can be increased when it is combined with Propafenone.Approved
AdrafinilThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Propafenone.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Propafenone.Approved
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Propafenone.Experimental, Investigational
Agrostis gigantea pollenThe risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Propafenone.Approved
Agrostis stolonifera pollenThe risk of a hypersensitivity reaction to Agrostis stolonifera pollen is increased when it is combined with Propafenone.Approved
AjmalinePropafenone may increase the arrhythmogenic activities of Ajmaline.Approved, Investigational
AlaproclateThe serum concentration of Propafenone can be increased when it is combined with Alaproclate.Experimental
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Propafenone.Approved
AlclofenacAlclofenac may decrease the antihypertensive activities of Propafenone.Approved, Withdrawn
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Propafenone.Experimental, Investigational
AlfentanilAlfentanil may increase the bradycardic activities of Propafenone.Approved, Illicit
AlfuzosinPropafenone may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineThe serum concentration of Propafenone can be increased when it is combined with Alimemazine.Approved, Vet Approved
AliskirenThe risk or severity of hyperkalemia can be increased when Aliskiren is combined with Propafenone.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Propafenone.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Propafenone.Experimental
AlosetronThe metabolism of Propafenone can be decreased when combined with Alosetron.Approved, Withdrawn
AlprenololThe risk or severity of adverse effects can be increased when Propafenone is combined with Alprenolol.Approved, Withdrawn
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Propafenone.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Propafenone.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Propafenone.Approved, Investigational
AmibegronThe therapeutic efficacy of Amibegron can be decreased when used in combination with Propafenone.Investigational
AmifampridineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Amifampridine.Approved
AmilorideThe risk or severity of hyperkalemia can be increased when Amiloride is combined with Propafenone.Approved
AminophenazoneAminophenazone may decrease the antihypertensive activities of Propafenone.Approved, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Propafenone.Approved, Investigational
AmitrazThe therapeutic efficacy of Amitraz can be decreased when used in combination with Propafenone.Vet Approved
AmitriptylinePropafenone may increase the orthostatic hypotensive activities of Amitriptyline.Approved
AmobarbitalThe serum concentration of Propafenone can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Propafenone.Approved, Investigational
AmoxapinePropafenone may increase the orthostatic hypotensive activities of Amoxapine.Approved
AmprenavirThe serum concentration of Propafenone can be increased when it is combined with Amprenavir.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Anagrelide.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Propafenone is combined with Anisodamine.Investigational
AntazolineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Antazoline.Approved
Anthoxanthum odoratum pollenThe risk of a hypersensitivity reaction to Anthoxanthum odoratum pollen is increased when it is combined with Propafenone.Approved
AntipyrineAntipyrine may decrease the antihypertensive activities of Propafenone.Approved, Investigational
AntrafenineAntrafenine may decrease the antihypertensive activities of Propafenone.Approved
ApalutamideThe serum concentration of Propafenone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Propafenone.Approved
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Propafenone.Approved, Investigational
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Propafenone.Approved
AprepitantThe serum concentration of Propafenone can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineThe therapeutic efficacy of Arbutamine can be decreased when used in combination with Propafenone.Approved
ArdeparinThe risk or severity of hyperkalemia can be increased when Ardeparin is combined with Propafenone.Approved, Investigational, Withdrawn
ArecolineThe risk or severity of adverse effects can be increased when Propafenone is combined with Arecoline.Experimental
ArformoterolThe therapeutic efficacy of Arformoterol can be decreased when used in combination with Propafenone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Propafenone.Approved, Investigational
Aripiprazole lauroxilThe serum concentration of aripiprazole, an active metabolite of Propafenone, can be increased when used in combination with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Propafenone is combined with Arotinolol.Investigational
Arrhenatherum elatius pollenThe risk of a hypersensitivity reaction to Arrhenatherum elatius pollen is increased when it is combined with Propafenone.Approved
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Artemether.Approved
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Propafenone.Approved, Nutraceutical
AsenapineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Propafenone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Propafenone is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Propafenone.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Propafenone.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Propafenone.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Propafenone.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Propafenone.Withdrawn
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Propafenone.Approved
AzathioprineThe serum concentration of Azathioprine can be increased when it is combined with Propafenone.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Azelastine is combined with Propafenone.Approved
Azilsartan medoxomilThe risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Propafenone.Approved, Investigational
AzimilidePropafenone may increase the arrhythmogenic activities of Azimilide.Investigational
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Propafenone.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Propafenone.Approved, Investigational
BambuterolThe therapeutic efficacy of Bambuterol can be decreased when used in combination with Propafenone.Approved, Investigational
BamifyllineThe serum concentration of Bamifylline can be increased when it is combined with Propafenone.Experimental
BarbexacloneThe serum concentration of Propafenone can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Propafenone can be decreased when it is combined with Barbital.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Propafenone.Approved, Investigational
BedaquilineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Bedaquiline.Approved
BefunololThe risk or severity of adverse effects can be increased when Propafenone is combined with Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Propafenone.Approved, Investigational
BemiparinThe risk or severity of hyperkalemia can be increased when Bemiparin is combined with Propafenone.Approved, Investigational
BenazeprilThe risk or severity of hyperkalemia can be increased when Benazepril is combined with Propafenone.Approved, Investigational
BenazeprilatThe risk or severity of hyperkalemia can be increased when Benazeprilat is combined with Propafenone.Experimental
BendazacBendazac may decrease the antihypertensive activities of Propafenone.Experimental
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Propafenone.Approved
BenorilateBenorilate may decrease the antihypertensive activities of Propafenone.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Propafenone.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Propafenone.Approved
BenzphetamineThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Propafenone.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Propafenone.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Bepridil.Approved, Withdrawn
BeractantPropafenone may increase the bradycardic activities of Beractant.Approved
BesifloxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Besifloxacin.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Propafenone.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Propafenone is combined with Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Propafenone is combined with Bethanechol.Approved
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Propafenone.Approved
BevantololThe risk or severity of adverse effects can be increased when Propafenone is combined with Bevantolol.Approved
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Propafenone.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Propafenone is combined with Bisoprolol.Approved
BitolterolThe therapeutic efficacy of Bitolterol can be decreased when used in combination with Propafenone.Withdrawn
BL-1020The serum concentration of Propafenone can be increased when it is combined with BL-1020.Investigational
BopindololThe risk or severity of adverse effects can be increased when Propafenone is combined with Bopindolol.Approved
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Propafenone.Approved, Investigational
BosentanThe serum concentration of Propafenone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Propafenone.Approved
Bouteloua gracilis pollenThe risk of a hypersensitivity reaction to Bouteloua gracilis pollen is increased when it is combined with Propafenone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Propafenone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Propafenone.Approved, Investigational
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Propafenone.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Propafenone.Approved
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Propafenone.Approved, Investigational
BromotheophyllineThe serum concentration of Bromotheophylline can be increased when it is combined with Propafenone.Approved
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Propafenone.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Propafenone.Approved
Bromus secalinus pollenThe risk of a hypersensitivity reaction to Bromus secalinus pollen is increased when it is combined with Propafenone.Approved
BucindololThe risk or severity of adverse effects can be increased when Propafenone is combined with Bucindolol.Investigational
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Propafenone.Approved
BufexamacBufexamac may decrease the antihypertensive activities of Propafenone.Approved, Experimental
BufuralolThe risk or severity of adverse effects can be increased when Propafenone is combined with Bufuralol.Experimental, Investigational
BufyllineThe serum concentration of Bufylline can be increased when it is combined with Propafenone.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Propafenone.Experimental
BunaftinePropafenone may increase the arrhythmogenic activities of Bunaftine.Experimental
BunazosinPropafenone may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Propafenone.Approved, Investigational
BupranololThe risk or severity of adverse effects can be increased when Propafenone is combined with Bupranolol.Approved
BupropionThe serum concentration of Propafenone can be increased when it is combined with Bupropion.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Propafenone.Approved, Investigational
ButaperazineThe serum concentration of Propafenone can be increased when it is combined with Butaperazine.Experimental
ButriptylineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Butriptyline.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Propafenone.Approved
CabergolinePropafenone may increase the vasoconstricting activities of Cabergoline.Approved
CafedrineThe serum concentration of Cafedrine can be increased when it is combined with Propafenone.Investigational
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Propafenone.Approved
CalfactantPropafenone may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Propafenone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Propafenone.Approved
CandesartanThe risk or severity of hyperkalemia can be increased when Candesartan is combined with Propafenone.Experimental
Candesartan cilexetilThe risk or severity of hyperkalemia can be increased when Candesartan cilexetil is combined with Propafenone.Approved
CaptoprilThe risk or severity of hyperkalemia can be increased when Captopril is combined with Propafenone.Approved
CarbamazepineThe serum concentration of Propafenone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbamoylcholineThe risk or severity of adverse effects can be increased when Propafenone is combined with Carbamoylcholine.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Propafenone.Experimental, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Carbinoxamine.Approved
CarbutamidePropafenone may increase the hypoglycemic activities of Carbutamide.Experimental
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Propafenone.Approved, Investigational
CarprofenCarprofen may decrease the antihypertensive activities of Propafenone.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Propafenone is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Propafenone is combined with Carvedilol.Approved, Investigational
CelecoxibCelecoxib may decrease the antihypertensive activities of Propafenone.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Propafenone is combined with Celiprolol.Approved, Investigational
CeritinibPropafenone may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Propafenone.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Propafenone.Approved, Investigational
CertoparinThe risk or severity of hyperkalemia can be increased when Certoparin is combined with Propafenone.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Propafenone.Approved
CevimelineThe risk or severity of adverse effects can be increased when Propafenone is combined with Cevimeline.Approved
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Propafenone.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Propafenone.Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Chlorphenamine.Approved
ChlorproethazineThe serum concentration of Propafenone can be increased when it is combined with Chlorproethazine.Experimental
ChlorpropamidePropafenone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Propafenone.Approved, Investigational, Withdrawn
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Propafenone.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Propafenone.Approved
CibenzolinePropafenone may increase the arrhythmogenic activities of Cibenzoline.Experimental
CilazaprilThe risk or severity of hyperkalemia can be increased when Cilazapril is combined with Propafenone.Approved
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Propafenone.Approved, Investigational
CimicoxibCimicoxib may decrease the antihypertensive activities of Propafenone.Investigational
CinacalcetThe serum concentration of Propafenone can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Propafenone.Approved, Investigational
CirazolineThe therapeutic efficacy of Cirazoline can be decreased when used in combination with Propafenone.Experimental
CisaprideThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Propafenone.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Propafenone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Clemastine can be increased when it is combined with Propafenone.Approved, Investigational
ClenbuterolThe therapeutic efficacy of Clenbuterol can be decreased when used in combination with Propafenone.Approved, Investigational, Vet Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Propafenone.Approved
ClonixinClonixin may decrease the antihypertensive activities of Propafenone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Propafenone.Approved
CloranololThe risk or severity of adverse effects can be increased when Propafenone is combined with Cloranolol.Experimental
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Propafenone.Experimental
ClotrimazoleThe serum concentration of Propafenone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapinePropafenone may increase the orthostatic hypotensive activities of Clozapine.Approved
CobicistatThe serum concentration of Propafenone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Propafenone.Approved, Investigational
CocaineThe serum concentration of Propafenone can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Propafenone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Propafenone.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Propafenone.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Propafenone.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Propafenone.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Propafenone.Vet Approved
CrizotinibThe serum concentration of Propafenone can be increased when it is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Propafenone is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Propafenone.Investigational
CurcuminThe serum concentration of Curcumin can be increased when it is combined with Propafenone.Approved, Investigational
CyamemazineThe serum concentration of Propafenone can be increased when it is combined with Cyamemazine.Approved
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Propafenone.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Propafenone.Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Propafenone.Experimental
Cynodon dactylon pollenThe risk of a hypersensitivity reaction to Cynodon dactylon pollen is increased when it is combined with Propafenone.Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Propafenone.Approved
Cyproterone acetateThe serum concentration of Propafenone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Propafenone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Propafenone.Approved
DabrafenibThe serum concentration of Propafenone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Propafenone.Approved, Investigational
Dactylis glomerata pollenThe risk of a hypersensitivity reaction to Dactylis glomerata pollen is increased when it is combined with Propafenone.Approved
DalteparinThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Propafenone.Approved
DanaparoidThe risk or severity of hyperkalemia can be increased when Danaparoid is combined with Propafenone.Approved, Withdrawn
DanazolThe serum concentration of Propafenone can be increased when it is combined with Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Propafenone.Approved
DapiprazolePropafenone may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DapoxetineThe serum concentration of Propafenone can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Propafenone.Approved, Investigational
DarunavirThe serum concentration of Propafenone can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Propafenone.Approved
DasatinibThe serum concentration of Propafenone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Propafenone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Propafenone.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Propafenone.Approved
DeferasiroxThe serum concentration of Propafenone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Propafenone.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Delamanid.Approved, Investigational
DelaprilThe risk or severity of hyperkalemia can be increased when Delapril is combined with Propafenone.Investigational
DelavirdineThe serum concentration of Propafenone can be increased when it is combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Propafenone.Approved
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Propafenone.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Propafenone.Approved, Investigational
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Propafenone.Approved
DesloratadineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Propafenone can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe therapeutic efficacy of Detomidine can be decreased when used in combination with Propafenone.Vet Approved
DeutetrabenazineThe serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Propafenone.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Propafenone.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Dexchlorpheniramine maleate.Approved
DexibuprofenDexibuprofen may decrease the antihypertensive activities of Propafenone.Approved, Investigational
DexketoprofenDexketoprofen may decrease the antihypertensive activities of Propafenone.Approved, Investigational
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Propafenone.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Propafenone.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Propafenone.Approved, Illicit, Investigational, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Propafenone.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Propafenone.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Propafenone.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propafenone.Approved, Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Propafenone.Experimental
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Propafenone.Vet Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Propafenone.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Propafenone.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Propafenone.Approved
DihydroergocorninePropafenone may increase the vasoconstricting activities of Dihydroergocornine.Approved
DihydroergocristinePropafenone may increase the vasoconstricting activities of Dihydroergocristine.Approved, Experimental
DihydroergocryptinePropafenone may increase the vasoconstricting activities of Dihydroergocryptine.Experimental
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Propafenone.Approved, Investigational
DiltiazemThe serum concentration of Propafenone can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Dimenhydrinate.Approved
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Propafenone.Experimental
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Propafenone.Approved, Investigational
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Propafenone.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Propafenone.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Propafenone.Approved
Distichlis spicata pollenThe risk of a hypersensitivity reaction to Distichlis spicata pollen is increased when it is combined with Propafenone.Approved
DistigmineDistigmine may increase the bradycardic activities of Propafenone.Experimental
DixyrazineThe serum concentration of Propafenone can be increased when it is combined with Dixyrazine.Experimental
DL-MethylephedrineThe therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Propafenone.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Propafenone.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Propafenone.Approved, Investigational
DofetilidePropafenone may increase the arrhythmogenic activities of Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Dolasetron is combined with Propafenone.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Propafenone.Approved
DomperidoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Propafenone.Approved
DopexamineThe therapeutic efficacy of Dopexamine can be decreased when used in combination with Propafenone.Approved, Investigational
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Propafenone.Approved
DoxazosinPropafenone may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinPropafenone may increase the orthostatic hypotensive activities of Doxepin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Propafenone.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Propafenone.Approved, Investigational
DoxycyclineThe serum concentration of Propafenone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Propafenone.Approved, Vet Approved
DronedaronePropafenone may increase the arrhythmogenic activities of Dronedarone.Approved
DroperidolPropafenone may increase the orthostatic hypotensive activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Propafenone.Withdrawn
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Propafenone.Approved, Investigational
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Propafenone.Approved, Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Propafenone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Propafenone.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Propafenone.Approved
EfavirenzThe serum concentration of Propafenone can be increased when it is combined with Efavirenz.Approved, Investigational
ElagolixThe metabolism of Elagolix can be decreased when combined with Propafenone.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Propafenone.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Propafenone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Propafenone.Approved
Elymus repens pollenThe risk of a hypersensitivity reaction to Elymus repens pollen is increased when it is combined with Propafenone.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Emedastine.Approved
EnalaprilThe risk or severity of hyperkalemia can be increased when Enalapril is combined with Propafenone.Approved, Vet Approved
EnalaprilatThe risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Propafenone.Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Propafenone.Approved, Investigational
EnoxaparinThe risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Propafenone.Approved
EntecavirThe serum concentration of Entecavir can be increased when it is combined with Propafenone.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Propafenone can be decreased when it is combined with Enzalutamide.Approved
EpanololThe risk or severity of adverse effects can be increased when Propafenone is combined with Epanolol.Experimental
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Propafenone.Approved, Nutraceutical, Withdrawn
EphedrineThe therapeutic efficacy of Ephedrine can be decreased when used in combination with Propafenone.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Propafenone is combined with Epibatidine.Experimental
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Propafenone.Approved, Investigational
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Propafenone.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Propafenone.Approved
EplerenoneThe risk or severity of hyperkalemia can be increased when Eplerenone is combined with Propafenone.Approved
EprosartanThe risk or severity of hyperkalemia can be increased when Eprosartan is combined with Propafenone.Approved
Ergoloid mesylatePropafenone may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineThe therapeutic efficacy of Ergonovine can be decreased when used in combination with Propafenone.Approved
ErgotaminePropafenone may increase the vasoconstricting activities of Ergotamine.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Propafenone.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Erlotinib.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Propafenone.Approved, Investigational
ErythromycinThe serum concentration of Propafenone can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe risk or severity of adverse effects can be increased when Propafenone is combined with Esatenolol.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Propafenone is combined with Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Propafenone.Approved
EtafedrineThe therapeutic efficacy of Etafedrine can be decreased when used in combination with Propafenone.Approved
EtamiphyllineThe serum concentration of Etamiphylline can be increased when it is combined with Propafenone.Experimental
EthenzamideEthenzamide may decrease the antihypertensive activities of Propafenone.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Propafenone.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Propafenone.Withdrawn
EtilefrineThe therapeutic efficacy of Etilefrine can be decreased when used in combination with Propafenone.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Propafenone.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Propafenone.Approved, Investigational
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Propafenone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Propafenone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Propafenone.Approved, Investigational
EtravirineThe serum concentration of Propafenone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Propafenone.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Propafenone.Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Propafenone.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Propafenone.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Propafenone.Approved
FelbinacFelbinac may decrease the antihypertensive activities of Propafenone.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Propafenone.Approved
FenethyllineThe serum concentration of Fenethylline can be increased when it is combined with Propafenone.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Propafenone.Approved
FenoterolThe therapeutic efficacy of Fenoterol can be decreased when used in combination with Propafenone.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Propafenone.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Propafenone.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Propafenone.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Propafenone.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propafenone.Approved
Festuca pratensis pollenThe risk of a hypersensitivity reaction to Festuca pratensis pollen is increased when it is combined with Propafenone.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Fexofenadine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Propafenone.Approved
FimasartanThe risk or severity of hyperkalemia can be increased when Fimasartan is combined with Propafenone.Approved, Investigational
FingolimodPropafenone may increase the bradycardic activities of Fingolimod.Approved, Investigational
FirocoxibFirocoxib may decrease the antihypertensive activities of Propafenone.Experimental, Vet Approved
FlecainideThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Propafenone.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Propafenone is combined with Floctafenine.Approved, Withdrawn
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Propafenone.Approved
FluconazoleThe serum concentration of Propafenone can be increased when it is combined with Fluconazole.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Propafenone.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Propafenone.Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Propafenone.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Propafenone.Experimental
FluoxetinePropafenone may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Propafenone can be increased when it is combined with Fluphenazine.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Propafenone.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Propafenone.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Propafenone.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Propafenone.Approved
FluvoxamineThe serum concentration of Propafenone can be increased when it is combined with Fluvoxamine.Approved, Investigational
ForasartanThe risk or severity of hyperkalemia can be increased when Forasartan is combined with Propafenone.Experimental
FormoterolThe therapeutic efficacy of Formoterol can be decreased when used in combination with Propafenone.Approved, Investigational
FosamprenavirThe serum concentration of Propafenone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Propafenone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Propafenone.Approved
FosinoprilThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Propafenone.Approved
FosinoprilatThe risk or severity of hyperkalemia can be increased when Fosinoprilat is combined with Propafenone.Experimental
FosphenytoinThe serum concentration of Propafenone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurafyllineThe serum concentration of Furafylline can be increased when it is combined with Propafenone.Experimental
Fusidic AcidThe serum concentration of Propafenone can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Propafenone.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Propafenone.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Propafenone.Approved
GanciclovirThe serum concentration of Ganciclovir can be increased when it is combined with Propafenone.Approved, Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Propafenone.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Propafenone.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Propafenone.Approved, Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Propafenone.Approved, Investigational, Nutraceutical
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Propafenone.Experimental
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Propafenone.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Propafenone.Approved, Investigational
GlibornuridePropafenone may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazidePropafenone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePropafenone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePropafenone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidonePropafenone may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepidePropafenone may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburidePropafenone may increase the hypoglycemic activities of Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Propafenone can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Propafenone.Approved
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Propafenone.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Granisetron is combined with Propafenone.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Propafenone.Approved
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Propafenone is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Propafenone.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Propafenone.Approved, Investigational
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Propafenone.Approved, Investigational
GuanineThe serum concentration of Guanine can be increased when it is combined with Propafenone.Experimental
HalofantrineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Propafenone.Approved
HeparinThe risk or severity of hyperkalemia can be increased when Heparin is combined with Propafenone.Approved, Investigational
HexobarbitalThe serum concentration of Propafenone can be decreased when it is combined with Hexobarbital.Approved
HexoprenalineThe therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Propafenone.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Higenamine can be decreased when used in combination with Propafenone.Investigational
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Propafenone.Approved
Holcus lanatus pollenThe risk of a hypersensitivity reaction to Holcus lanatus pollen is increased when it is combined with Propafenone.Approved
Huperzine AHuperzine A may increase the bradycardic activities of Propafenone.Approved, Investigational
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Propafenone resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Propafenone.Approved, Vet Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Propafenone.Approved
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Propafenone.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Propafenone.Approved
HypoxanthineThe serum concentration of Hypoxanthine can be increased when it is combined with Propafenone.Experimental
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propafenone.Approved, Investigational
IbuprofenIbuprofen may decrease the antihypertensive activities of Propafenone.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Propafenone.Withdrawn
IbutilidePropafenone may increase the arrhythmogenic activities of Ibutilide.Approved
IcosapentIcosapent may decrease the antihypertensive activities of Propafenone.Approved, Nutraceutical
IdelalisibThe serum concentration of Propafenone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Propafenone.Approved
ImatinibThe serum concentration of Propafenone can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of hyperkalemia can be increased when Imidapril is combined with Propafenone.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Propafenone.Experimental
ImipraminePropafenone may increase the orthostatic hypotensive activities of Imipramine.Approved
IndacaterolThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Propafenone.Approved
IndalpineThe serum concentration of Propafenone can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Propafenone.Approved
IndenololThe risk or severity of adverse effects can be increased when Propafenone is combined with Indenolol.Withdrawn
IndinavirThe serum concentration of Propafenone can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Propafenone.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Propafenone.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Propafenone.Withdrawn
IndoraminPropafenone may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Propafenone.Approved, Investigational
Insulin AspartPropafenone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DegludecPropafenone may increase the hypoglycemic activities of Insulin Degludec.Approved
Insulin DetemirPropafenone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePropafenone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePropafenone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPropafenone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPropafenone may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin peglisproPropafenone may increase the hypoglycemic activities of Insulin peglispro.Investigational
Insulin PorkPropafenone may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Propafenone.Experimental
IrbesartanThe risk or severity of hyperkalemia can be increased when Irbesartan is combined with Propafenone.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Propafenone.Approved, Investigational
IsavuconazoleThe serum concentration of Propafenone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Propafenone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoetarineThe therapeutic efficacy of Isoetarine can be decreased when used in combination with Propafenone.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Propafenone.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Propafenone.Approved, Investigational, Withdrawn
IsomethepteneThe therapeutic efficacy of Isometheptene can be decreased when used in combination with Propafenone.Approved
IsoniazidThe serum concentration of Propafenone can be increased when it is combined with Isoniazid.Approved, Investigational
IsoprenalineThe therapeutic efficacy of Isoprenaline can be decreased when used in combination with Propafenone.Approved, Investigational
IsoxicamIsoxicam may decrease the antihypertensive activities of Propafenone.Withdrawn
IsoxsuprineThe therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Propafenone.Approved, Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Propafenone.Approved, Investigational
ItoprideItopride may increase the bradycardic activities of Propafenone.Investigational
ItraconazoleThe serum concentration of Propafenone can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradinePropafenone may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Propafenone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Ivosidenib.Approved, Investigational
KebuzoneKebuzone may decrease the antihypertensive activities of Propafenone.Experimental
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Propafenone.Approved
KetoconazoleThe serum concentration of Propafenone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Propafenone.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Propafenone.Approved
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Propafenone.Approved
Koeleria macrantha pollenThe risk of a hypersensitivity reaction to Koeleria macrantha pollen is increased when it is combined with Propafenone.Approved
LabetalolThe risk or severity of adverse effects can be increased when Propafenone is combined with Labetalol.Approved
LacosamidePropafenone may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Propafenone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Propafenone.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Propafenone.Experimental
LandiololThe risk or severity of adverse effects can be increased when Propafenone is combined with Landiolol.Investigational
LanreotidePropafenone may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Propafenone.Approved, Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Propafenone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Propafenone.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Propafenone.Approved
LenvatinibThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Lenvatinib.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Propafenone.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Propafenone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Propafenone.Approved, Investigational
LevobetaxololThe risk or severity of adverse effects can be increased when Propafenone is combined with Levobetaxolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Propafenone is combined with Levobunolol.Approved
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Propafenone.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Propafenone.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Propafenone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe serum concentration of Propafenone can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevosalbutamolThe therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Propafenone.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Propafenone.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Propafenone.Approved
LisinoprilThe risk or severity of hyperkalemia can be increased when Lisinopril is combined with Propafenone.Approved, Investigational
LisofyllineThe serum concentration of Lisofylline can be increased when it is combined with Propafenone.Investigational
LisuridePropafenone may increase the vasoconstricting activities of Lisuride.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Lithium cation.Experimental
LobeglitazoneThe metabolism of Propafenone can be decreased when combined with Lobeglitazone.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Propafenone is combined with Lobeline.Investigational
LobucavirThe serum concentration of Lobucavir can be increased when it is combined with Propafenone.Investigational
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Propafenone.Approved, Investigational
Lolium perenne pollenThe risk of a hypersensitivity reaction to Lolium perenne pollen is increased when it is combined with Propafenone.Approved
Lolium perenne subsp. multiflorum pollenThe risk of a hypersensitivity reaction to Lolium perenne subsp. multiflorum pollen is increased when it is combined with Propafenone.Approved
LomefloxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Lomefloxacin.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Propafenone.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Propafenone.Approved
LopinavirThe serum concentration of Lopinavir can be increased when it is combined with Propafenone.Approved
LorajminePropafenone may increase the arrhythmogenic activities of Lorajmine.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Loratadine.Approved, Investigational
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Propafenone.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Propafenone.Approved, Investigational
LorpiprazoleThe serum concentration of Propafenone can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Propafenone.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Propafenone.Approved, Investigational
LucinactantPropafenone may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Propafenone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Propafenone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Propafenone.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Propafenone.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Propafenone.Approved, Investigational
Lysergic Acid DiethylamidePropafenone may increase the vasoconstricting activities of Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
MacimorelinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Macimorelin.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Propafenone.Approved
MalathionMalathion may increase the bradycardic activities of Propafenone.Approved, Investigational
ManidipineThe serum concentration of Manidipine can be increased when it is combined with Propafenone.Approved, Investigational
MannitolThe risk or severity of hyperkalemia can be increased when Propafenone is combined with Mannitol.Approved, Investigational
Mannitol busulfanThe risk or severity of hyperkalemia can be increased when Propafenone is combined with Mannitol busulfan.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Propafenone.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Propafenone.Approved, Vet Approved
MedetomidineThe therapeutic efficacy of Medetomidine can be decreased when used in combination with Propafenone.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Propafenone.Approved
MefloquineThe risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Propafenone.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Propafenone.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Propafenone.Approved
MephentermineThe therapeutic efficacy of Mephentermine can be decreased when used in combination with Propafenone.Approved
MepindololThe risk or severity of adverse effects can be increased when Propafenone is combined with Mepindolol.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Propafenone.Approved, Vet Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Propafenone.Approved, Vet Approved
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Propafenone.Approved
MesalazineMesalazine may decrease the antihypertensive activities of Propafenone.Approved
MesoridazineThe serum concentration of Propafenone can be increased when it is combined with Mesoridazine.Approved, Investigational
MetahexamidePropafenone may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Propafenone.Approved, Investigational, Withdrawn
MetaraminolThe therapeutic efficacy of Metaraminol can be decreased when used in combination with Propafenone.Approved, Investigational
MetergolinePropafenone may increase the vasoconstricting activities of Metergoline.Experimental
MethacholinePropafenone may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethadoneThe serum concentration of Methadone can be increased when it is combined with Propafenone.Approved
MethamphetamineThe therapeutic efficacy of Methamphetamine can be decreased when used in combination with Propafenone.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Propafenone.Investigational
MethohexitalThe serum concentration of Propafenone can be decreased when it is combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Propafenone.Approved
MethoxamineThe therapeutic efficacy of Methoxamine can be decreased when used in combination with Propafenone.Approved, Investigational
MethoxyphenamineThe therapeutic efficacy of Methoxyphenamine can be decreased when used in combination with Propafenone.Experimental
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Propafenone.Approved
Methylene blueThe serum concentration of Propafenone can be increased when it is combined with Methylene blue.Approved, Investigational
MethylergometrinePropafenone may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Propafenone can be decreased when it is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Propafenone.Approved, Vet Approved
MethysergidePropafenone may increase the vasoconstricting activities of Methysergide.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Propafenone.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Propafenone is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Propafenone.Approved, Investigational
MetoprololThe risk or severity of adverse effects can be increased when Propafenone is combined with Metoprolol.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Propafenone.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Propafenone.Approved, Investigational
MibefradilThe serum concentration of Propafenone can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Propafenone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Propafenone can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Propafenone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Propafenone can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Propafenone.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Propafenone.Approved
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Propafenone.Approved
MitotaneThe serum concentration of Propafenone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Propafenone.Approved, Investigational
MocetinostatThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Mocetinostat.Investigational
ModafinilThe serum concentration of Propafenone can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Propafenone.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Propafenone.Experimental
MoricizineThe serum concentration of Propafenone can be increased when it is combined with Moricizine.Approved, Investigational, Withdrawn
MorniflumateMorniflumate may decrease the antihypertensive activities of Propafenone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Propafenone.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Propafenone.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Propafenone.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propafenone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Propafenone.Approved
NadololThe risk or severity of adverse effects can be increased when Propafenone is combined with Nadolol.Approved
NadroparinThe risk or severity of hyperkalemia can be increased when Nadroparin is combined with Propafenone.Approved, Investigational
NafcillinThe serum concentration of Propafenone can be decreased when it is combined with Nafcillin.Approved, Investigational
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Propafenone.Approved
NaloxoneThe serum concentration of Propafenone can be increased when it is combined with Naloxone.Approved, Vet Approved
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Propafenone.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Propafenone.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Propafenone is combined with Nebivolol.Approved, Investigational
NelfinavirThe serum concentration of Propafenone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Nemonoxacin.Investigational
NeostigmineNeostigmine may increase the bradycardic activities of Propafenone.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Propafenone.Approved, Investigational
NetupitantThe serum concentration of Propafenone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Propafenone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Propafenone can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolinePropafenone may increase the vasoconstricting activities of Nicergoline.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Propafenone is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Propafenone.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Propafenone.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Propafenone.Approved
NiguldipinePropafenone may increase the orthostatic hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Propafenone.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Propafenone.Approved, Investigational, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Propafenone.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Propafenone.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Propafenone.Approved
NN344Propafenone may increase the hypoglycemic activities of NN344.Investigational
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Propafenone.Approved
NorfenefrineThe therapeutic efficacy of Norfenefrine can be decreased when used in combination with Propafenone.Experimental
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Propafenone.Approved
NortriptylinePropafenone may increase the orthostatic hypotensive activities of Nortriptyline.Approved
NS-398NS-398 may decrease the antihypertensive activities of Propafenone.Experimental
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Propafenone.Approved
OctopamineThe therapeutic efficacy of Octopamine can be decreased when used in combination with Propafenone.Experimental
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Propafenone.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Propafenone.Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Propafenone.Approved
OlanzapinePropafenone may increase the orthostatic hypotensive activities of Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Propafenone can be increased when it is combined with Olaparib.Approved
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Propafenone.Experimental, Investigational
OlmesartanThe risk or severity of hyperkalemia can be increased when Olmesartan is combined with Propafenone.Approved, Investigational
OlodaterolThe therapeutic efficacy of Olodaterol can be decreased when used in combination with Propafenone.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Propafenone.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Propafenone.Approved
OmapatrilatThe risk or severity of hyperkalemia can be increased when Omapatrilat is combined with Propafenone.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Propafenone.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Propafenone.Approved
OpipramolThe metabolism of Opipramol can be decreased when combined with Propafenone.Investigational
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Propafenone.Vet Approved
OrciprenalineThe therapeutic efficacy of Orciprenaline can be decreased when used in combination with Propafenone.Approved
OrlistatThe serum concentration of Propafenone can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineThe risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Propafenone.Approved
OuabainThe serum concentration of Ouabain can be increased when it is combined with Propafenone.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Oxaliplatin.Approved, Investigational
OxaprozinOxaprozin may decrease the antihypertensive activities of Propafenone.Approved
OxatomideThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Oxatomide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Propafenone.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Propafenone is combined with Oxprenolol.Approved
OxtriphyllineThe serum concentration of Oxtriphylline can be increased when it is combined with Propafenone.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Propafenone.Approved, Illicit, Investigational
OxyfedrineThe therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Propafenone.Experimental
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propafenone.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Propafenone.Approved, Withdrawn
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propafenone.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Propafenone.Approved, Vet Approved
PalbociclibThe serum concentration of Propafenone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Propafenone can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Propafenone.Approved
PapaverineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Papaverine.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Propafenone.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Propafenone.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Propafenone.Approved, Investigational
ParnaparinThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Propafenone.Approved, Investigational
Pascopyrum smithii pollenThe risk of a hypersensitivity reaction to Pascopyrum smithii pollen is increased when it is combined with Propafenone.Approved
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Propafenone.Approved
Paspalum notatum pollenThe risk of a hypersensitivity reaction to Paspalum notatum pollen is increased when it is combined with Propafenone.Approved
Patent BlueThe risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Propafenone.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Propafenone.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Propafenone.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Propafenone.Approved
Peginterferon alfa-2bThe serum concentration of Propafenone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PeldesineThe serum concentration of Peldesine can be increased when it is combined with Propafenone.Experimental, Investigational
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Propafenone.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Propafenone is combined with Penbutolol.Approved, Investigational
PenciclovirThe serum concentration of Penciclovir can be increased when it is combined with Propafenone.Approved
Penicillin G Acyl-SerineThe risk or severity of hyperkalemia can be increased when Propafenone is combined with Penicillin G Acyl-Serine.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Pentamidine is combined with Propafenone.Approved, Investigational
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Propafenone.Approved, Vet Approved
PentifyllineThe serum concentration of Pentifylline can be increased when it is combined with Propafenone.Experimental
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Propafenone.Approved, Investigational
PerazineThe serum concentration of Propafenone can be increased when it is combined with Perazine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Perflutren is combined with Propafenone.Approved
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Propafenone.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of hyperkalemia can be increased when Perindopril is combined with Propafenone.Approved
PerindoprilatThe risk or severity of hyperkalemia can be increased when Perindoprilat is combined with Propafenone.Experimental
PerphenazineThe serum concentration of Propafenone can be increased when it is combined with Perphenazine.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Propafenone.Experimental
PF-00610355The therapeutic efficacy of PF-00610355 can be decreased when used in combination with Propafenone.Investigational
Phalaris arundinacea pollenThe risk of a hypersensitivity reaction to Phalaris arundinacea pollen is increased when it is combined with Propafenone.Approved
Phalaris minor pollenThe risk of a hypersensitivity reaction to Phalaris minor pollen is increased when it is combined with Propafenone.Approved
PhendimetrazineThe therapeutic efficacy of Phendimetrazine can be decreased when used in combination with Propafenone.Approved, Illicit
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Propafenone.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Propafenone.Approved
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Propafenone.Vet Approved
PhenoxybenzaminePropafenone may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Propafenone.Approved, Investigational
PhentolaminePropafenone may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Propafenone.Approved, Vet Approved
Phenylbutyric acidThe serum concentration of Phenylbutyric acid can be increased when it is combined with Propafenone.Approved, Investigational
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Propafenone.Approved
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Propafenone.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Propafenone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
Phleum pratense pollenThe risk of a hypersensitivity reaction to Phleum pratense pollen is increased when it is combined with Propafenone.Approved, Investigational
PhysostigminePhysostigmine may increase the bradycardic activities of Propafenone.Approved, Investigational
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Propafenone.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Propafenone is combined with Pilocarpine.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Propafenone.Approved
PindololThe risk or severity of adverse effects can be increased when Propafenone is combined with Pindolol.Approved, Investigational
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Propafenone.Experimental
PipotiazineThe serum concentration of Propafenone can be increased when it is combined with Pipotiazine.Approved, Investigational
PirbuterolThe therapeutic efficacy of Pirbuterol can be decreased when used in combination with Propafenone.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Propafenone.Experimental
PiroxicamPiroxicam may decrease the antihypertensive activities of Propafenone.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Propafenone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Propafenone.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Propafenone.Approved, Investigational
PizotifenPropafenone may increase the orthostatic hypotensive activities of Pizotifen.Approved
Poa annua pollenThe risk of a hypersensitivity reaction to Poa annua pollen is increased when it is combined with Propafenone.Approved
Poa compressa pollenThe risk of a hypersensitivity reaction to Poa compressa pollen is increased when it is combined with Propafenone.Approved
Poa pratensis pollenThe risk of a hypersensitivity reaction to Poa pratensis pollen is increased when it is combined with Propafenone.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Propafenone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Propafenone.Approved, Investigational
Poractant alfaPropafenone may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Propafenone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Propafenone.Approved, Investigational
Potassium bicarbonateThe risk or severity of hyperkalemia can be increased when Potassium bicarbonate is combined with Propafenone.Approved
Potassium cationThe risk or severity of hyperkalemia can be increased when Potassium cation is combined with Propafenone.Approved, Investigational
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Propafenone.Approved, Withdrawn
Potassium CitrateThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Propafenone.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Pracinostat.Investigational
PractololThe risk or severity of adverse effects can be increased when Propafenone is combined with Practolol.Approved
PrajmalinePropafenone may increase the arrhythmogenic activities of Prajmaline.Experimental
PranoprofenPranoprofen may decrease the antihypertensive activities of Propafenone.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Propafenone.Approved
PrazosinPropafenone may increase the orthostatic hypotensive activities of Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Propafenone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Propafenone.Approved, Vet Approved
PrenalterolThe therapeutic efficacy of Prenalterol can be decreased when used in combination with Propafenone.Experimental
PrimaquineThe risk or severity of QTc prolongation can be decreased when Primaquine is combined with Propafenone.Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Probucol.Approved, Investigational
ProcainamidePropafenone may increase the arrhythmogenic activities of Procainamide.Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Procainamide.Approved
ProcaterolThe therapeutic efficacy of Procaterol can be decreased when used in combination with Propafenone.Approved, Investigational
ProchlorperazineThe serum concentration of Propafenone can be increased when it is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Propafenone.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Propafenone.Experimental
PromazineThe serum concentration of Propafenone can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Propafenone can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Propafenone.Approved, Investigational
PropentofyllineThe serum concentration of Propentofylline can be increased when it is combined with Propafenone.Investigational
PropericiazineThe serum concentration of Propafenone can be increased when it is combined with Propericiazine.Approved, Investigational
PropiomazinePropafenone may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazineThe serum concentration of Propafenone can be increased when it is combined with Propiopromazine.Vet Approved
PropiverinePropafenone may increase the orthostatic hypotensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Propafenone.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Propafenone.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Propafenone.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Propafenone.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Propafenone.Experimental
ProtokylolThe therapeutic efficacy of Protokylol can be decreased when used in combination with Propafenone.Approved, Vet Approved
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Propafenone.Approved
ProxyphyllineThe serum concentration of Proxyphylline can be increased when it is combined with Propafenone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Propafenone.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Propafenone.Investigational
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Propafenone.Approved
PyridostigminePyridostigmine may increase the bradycardic activities of Propafenone.Approved, Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Quetiapine.Approved
QuinaprilThe risk or severity of hyperkalemia can be increased when Quinapril is combined with Propafenone.Approved, Investigational
QuinaprilatThe risk or severity of hyperkalemia can be increased when Quinaprilat is combined with Propafenone.Experimental
QuinidinePropafenone may increase the arrhythmogenic activities of Quinidine.Approved, Investigational
QuinineThe serum concentration of Propafenone can be decreased when it is combined with Quinine.Approved
RacepinephrineThe therapeutic efficacy of Racepinephrine can be decreased when used in combination with Propafenone.Approved
RactopamineThe therapeutic efficacy of Ractopamine can be decreased when used in combination with Propafenone.Vet Approved
RamiprilThe risk or severity of hyperkalemia can be increased when Ramipril is combined with Propafenone.Approved
RamiprilatThe risk or severity of hyperkalemia can be increased when Ramiprilat is combined with Propafenone.Experimental
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Propafenone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Propafenone.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Propafenone.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Propafenone.Approved
ReproterolThe therapeutic efficacy of Reproterol can be decreased when used in combination with Propafenone.Investigational
RescinnamineThe risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Propafenone.Approved
ReserpineReserpine may increase the hypotensive activities of Propafenone.Approved, Investigational
ReviparinThe risk or severity of hyperkalemia can be increased when Reviparin is combined with Propafenone.Approved, Investigational
RheinThe serum concentration of Rhein can be increased when it is combined with Propafenone.Experimental
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Propafenone.Experimental
RibociclibThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Ricolinostat.Investigational
RifampicinThe serum concentration of Propafenone can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Propafenone can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Propafenone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Propafenone.Approved, Investigational
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Propafenone.Approved, Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Propafenone.Approved
RimexoloneThe serum concentration of Propafenone can be decreased when it is combined with Rimexolone.Approved
RimiterolThe therapeutic efficacy of Rimiterol can be decreased when used in combination with Propafenone.Experimental
RisperidoneThe serum concentration of Propafenone can be increased when it is combined with Risperidone.Approved, Investigational
RitanserinThe serum concentration of Propafenone can be increased when it is combined with Ritanserin.Investigational
RitobegronThe therapeutic efficacy of Ritobegron can be decreased when used in combination with Propafenone.Investigational
RitodrineThe therapeutic efficacy of Ritodrine can be decreased when used in combination with Propafenone.Approved, Investigational
RitonavirThe serum concentration of Propafenone can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Propafenone.Approved
RivastigminePropafenone may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RobenacoxibRobenacoxib may decrease the antihypertensive activities of Propafenone.Experimental, Vet Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Propafenone.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Propafenone.Approved, Investigational
RomidepsinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Romidepsin.Approved, Investigational
RomifidineThe therapeutic efficacy of Romifidine can be decreased when used in combination with Propafenone.Vet Approved
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Propafenone.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Propafenone.Approved, Investigational
RoxithromycinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Roxithromycin.Approved, Investigational, Withdrawn
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Propafenone.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Propafenone.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Propafenone.Approved
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Propafenone.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Propafenone.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Propafenone.Approved, Investigational, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Propafenone.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Propafenone.Approved
SaprisartanThe risk or severity of hyperkalemia can be increased when Saprisartan is combined with Propafenone.Experimental
SaquinavirSaquinavir may increase the arrhythmogenic activities of Propafenone.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Propafenone.Vet Approved, Withdrawn
SaralasinThe risk or severity of hyperkalemia can be increased when Saralasin is combined with Propafenone.Investigational
SarilumabThe therapeutic efficacy of Propafenone can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236SC-236 may decrease the antihypertensive activities of Propafenone.Experimental, Investigational
Secale cereale pollenThe risk of a hypersensitivity reaction to Secale cereale pollen is increased when it is combined with Propafenone.Approved
SecobarbitalThe serum concentration of Propafenone can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Propafenone.Approved
SertralineSertraline may increase the QTc-prolonging activities of Propafenone.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Propafenone.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Propafenone.Approved
SiltuximabThe serum concentration of Propafenone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Propafenone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Propafenone.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Propafenone.Approved, Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Propafenone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Propafenone.Approved
SolabegronThe therapeutic efficacy of Solabegron can be decreased when used in combination with Propafenone.Investigational
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Propafenone.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Propafenone.Approved, Investigational
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Propafenone.Approved, Investigational
Sorghum bicolor subsp. drummondii pollenThe risk of a hypersensitivity reaction to Sorghum bicolor subsp. drummondii pollen is increased when it is combined with Propafenone.Approved
Sorghum halepense pollenThe risk of a hypersensitivity reaction to Sorghum halepense pollen is increased when it is combined with Propafenone.Approved
SotalolThe risk or severity of adverse effects can be increased when Propafenone is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Sparfloxacin.Approved, Investigational
SparteinePropafenone may increase the arrhythmogenic activities of Sparteine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Propafenone.Experimental
SpiraprilThe risk or severity of hyperkalemia can be increased when Spirapril is combined with Propafenone.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Propafenone.Approved
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Propafenone.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Propafenone.Experimental
StiripentolThe serum concentration of Propafenone can be increased when it is combined with Stiripentol.Approved
SuccinylcholineThe risk or severity of hyperkalemia can be increased when Propafenone is combined with Succinylcholine.Approved
SufentanilSufentanil may increase the bradycardic activities of Propafenone.Approved, Investigational
SulconazoleThe serum concentration of Sulconazole can be increased when it is combined with Propafenone.Approved
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Propafenone.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Propafenone.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Propafenone.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Propafenone.Approved, Investigational
SulodexideThe risk or severity of hyperkalemia can be increased when Sulodexide is combined with Propafenone.Approved, Investigational
SulpirideThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Sultopride.Experimental
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Propafenone.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Propafenone.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Propafenone.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Propafenone.Experimental
SynephrineThe therapeutic efficacy of Synephrine can be decreased when used in combination with Propafenone.Experimental
TacrineTacrine may increase the bradycardic activities of Propafenone.Investigational, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Propafenone.Approved, Investigational
TafenoquineThe metabolism of Tafenoquine can be decreased when combined with Propafenone.Approved, Investigational
TalinololThe risk or severity of adverse effects can be increased when Propafenone is combined with Talinolol.Investigational
TalniflumateTalniflumate may decrease the antihypertensive activities of Propafenone.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Propafenone.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Propafenone.Approved, Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Propafenone.Investigational
TasosartanThe risk or severity of hyperkalemia can be increased when Tasosartan is combined with Propafenone.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Propafenone.Experimental
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Technetium Tc-99m ciprofloxacin.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Propafenone.Approved, Investigational
TedisamilPropafenone may increase the arrhythmogenic activities of Tedisamil.Investigational
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Propafenone.Approved, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Telavancin.Approved
TelithromycinThe serum concentration of Propafenone can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of hyperkalemia can be increased when Telmisartan is combined with Propafenone.Approved, Investigational
TemafloxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Temafloxacin.Withdrawn
TemocaprilThe risk or severity of hyperkalemia can be increased when Temocapril is combined with Propafenone.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Propafenone.Approved
TenidapTenidap may decrease the antihypertensive activities of Propafenone.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Propafenone.Approved
TenoxicamTenoxicam may decrease the antihypertensive activities of Propafenone.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Propafenone.Vet Approved
TerazosinPropafenone may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe serum concentration of Propafenone can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Propafenone.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Terfenadine.Approved, Withdrawn
TerguridePropafenone may increase the vasoconstricting activities of Terguride.Experimental
TeriflunomideThe serum concentration of Propafenone can be decreased when it is combined with Teriflunomide.Approved
TerlipressinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Terodiline.Experimental
TertatololThe risk or severity of adverse effects can be increased when Propafenone is combined with Tertatolol.Experimental
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Propafenone.Approved, Investigational, Vet Approved, Withdrawn
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Propafenone.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Propafenone.Approved, Vet Approved
TetryzolineThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Propafenone.Approved
TheobromineThe serum concentration of Theobromine can be increased when it is combined with Propafenone.Approved, Investigational
TheodrenalineThe serum concentration of Theodrenaline can be increased when it is combined with Propafenone.Investigational
TheophyllineThe metabolism of Propafenone can be decreased when combined with Theophylline.Approved
ThiamylalThe serum concentration of Propafenone can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe serum concentration of Propafenone can be increased when it is combined with Thiazinam.Experimental
ThiethylperazineThe serum concentration of Propafenone can be increased when it is combined with Thiethylperazine.Withdrawn
ThiopentalThe serum concentration of Propafenone can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe serum concentration of Propafenone can be increased when it is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propafenone.Approved, Withdrawn
ThiothixeneThe serum concentration of Thiothixene can be increased when it is combined with Propafenone.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Propafenone.Approved
TimololThe risk or severity of adverse effects can be increased when Propafenone is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Propafenone.Investigational
TinzaparinThe risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Propafenone.Approved
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Propafenone.Experimental
TipranavirThe serum concentration of Propafenone can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Propafenone.Approved, Investigational
TocilizumabThe serum concentration of Propafenone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Propafenone.Approved, Investigational
TolazamidePropafenone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolinePropafenone may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePropafenone may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Propafenone.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Propafenone.Approved
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Propafenone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Propafenone.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Propafenone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Propafenone.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Toremifene.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Propafenone.Approved, Investigational
TrandolaprilThe risk or severity of hyperkalemia can be increased when Trandolapril is combined with Propafenone.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Propafenone.Approved, Investigational
TrazodoneThe serum concentration of Propafenone can be increased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Propafenone.Approved, Investigational
TretoquinolThe therapeutic efficacy of Tretoquinol can be decreased when used in combination with Propafenone.Experimental
TriamtereneThe risk or severity of hyperkalemia can be increased when Triamterene is combined with Propafenone.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Propafenone.Vet Approved
TrifluoperazineThe serum concentration of Propafenone can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Propafenone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinPropafenone may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Propafenone.Approved, Vet Approved
TrimipraminePropafenone may increase the orthostatic hypotensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Propafenone.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Propafenone.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Propafenone.Approved
TroleandomycinThe serum concentration of Propafenone can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineTubocurarine may increase the bradycardic activities of Propafenone.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Tucidinostat.Investigational
TulobuterolThe therapeutic efficacy of Tulobuterol can be decreased when used in combination with Propafenone.Investigational
TyrothricinTyrothricin may increase the bradycardic activities of Propafenone.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Propafenone.Approved, Investigational, Nutraceutical
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Propafenone.Approved
UrapidilPropafenone may increase the orthostatic hypotensive activities of Urapidil.Investigational
Uric AcidThe serum concentration of Uric Acid can be increased when it is combined with Propafenone.Experimental, Investigational
Urochloa mutica pollenThe risk of a hypersensitivity reaction to Urochloa mutica pollen is increased when it is combined with Propafenone.Approved
ValaciclovirThe serum concentration of Valaciclovir can be increased when it is combined with Propafenone.Approved, Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Propafenone.Approved, Investigational, Withdrawn
ValganciclovirThe serum concentration of Valganciclovir can be increased when it is combined with Propafenone.Approved, Investigational
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Propafenone.Experimental
ValomaciclovirThe serum concentration of Valomaciclovir can be increased when it is combined with Propafenone.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of hyperkalemia can be increased when Valsartan is combined with Propafenone.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Propafenone.Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Propafenone.Approved
VareniclineThe risk or severity of adverse effects can be increased when Propafenone is combined with Varenicline.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Propafenone.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Propafenone.Approved, Investigational
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Propafenone.Approved, Investigational
VerapamilThe serum concentration of Propafenone can be increased when it is combined with Verapamil.Approved
VilanterolThe therapeutic efficacy of Vilanterol can be decreased when used in combination with Propafenone.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Propafenone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Propafenone.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Propafenone.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Propafenone.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Propafenone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Propafenone.Approved, Investigational
VoriconazoleThe serum concentration of Propafenone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Propafenone.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Propafenone.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Propafenone.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Propafenone.Approved
XamoterolThe therapeutic efficacy of Xamoterol can be decreased when used in combination with Propafenone.Experimental
XanthineThe serum concentration of Xanthine can be increased when it is combined with Propafenone.Experimental
XylazineThe therapeutic efficacy of Xylazine can be decreased when used in combination with Propafenone.Vet Approved
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Propafenone.Approved, Investigational
ZafirlukastThe metabolism of Propafenone can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Propafenone.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Propafenone.Approved
ZimelidineThe serum concentration of Propafenone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Propafenone can be increased when it is combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of hyperkalemia can be increased when Zofenopril is combined with Propafenone.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Propafenone.Withdrawn
ZucapsaicinThe metabolism of Propafenone can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Always take at the same time in regard to meals.
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.

References

Synthesis Reference

Helmut Lietz, "Preparation of propafenone." U.S. Patent US4474986, issued May, 1974.

US4474986
General References
Not Available
External Links
Human Metabolome Database
HMDB0015313
KEGG Compound
C07381
PubChem Compound
4932
PubChem Substance
46504529
ChemSpider
4763
BindingDB
50067133
ChEBI
63619
ChEMBL
CHEMBL631
Therapeutic Targets Database
DAP000497
PharmGKB
PA451131
IUPHAR
2561
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Propafenone
ATC Codes
C01BC03 — Propafenone
AHFS Codes
  • 24:04.04.12 — Class IC Antiarrythmics
FDA label
Download (91.1 KB)
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableCardiac Dysrhythmia1
2CompletedTreatmentFailed First Radiofrequency Ablation Procedure / Paroxysmal Atrial Fibrillation (PAF)1
3CompletedPreventionArrythmias / Cardiovascular Disease (CVD) / Heart Arrest / Heart Diseases / Myocardial Infarction / Severe ventricular arrhythmias1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentParoxysmal Atrial Fibrillation (PAF)1
3SuspendedTreatmentNonvalvular Atrial Fibrillation1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
4Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
4RecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableActive Not RecruitingTreatmentNonvalvular Atrial Fibrillation / Quality of Life1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation3
Not AvailableRecruitingTreatmentHeart Failure, Unspecified / Recurrent Atrial Fibrillation1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentPersistent Atrial Fibrillation1
Not AvailableRecruitingTreatmentPremature Ventricular Complex1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Abbott Laboratories Ltd.
  • Amerisource Health Services Corp.
  • A-S Medication Solutions LLC
  • BASF Corp.
  • Cardinal Health
  • Ethex Corp.
  • GlaxoSmithKline Inc.
  • Heartland Repack Services LLC
  • KV Pharmaceutical Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Neuman Distributors Inc.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Qualitest
  • Reliant Pharmaceuticals
  • Resource Optimization and Innovation LLC
  • UDL Laboratories
  • Vangard Labs Inc.
  • Vintage Pharmaceuticals Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral150 mg
TabletOral300 mg
Capsule, extended releaseOral225 1/1
Tablet, coatedOral150 mg/1
Tablet, coatedOral225 mg/1
Tablet, coatedOral300 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral225 mg/1
Tablet, film coatedOral300 mg/1
Capsule, extended releaseOral225 mg/1
Capsule, extended releaseOral325 mg/1
Capsule, extended releaseOral425 mg/1
Prices
Unit descriptionCostUnit
Rythmol SR 325 mg 12 Hour Capsule8.9USD capsule
Rythmol SR 425 mg 12 Hour Capsule8.9USD capsule
Rythmol sr 325 mg capsule8.56USD capsule
Rythmol sr 425 mg capsule8.56USD capsule
Rythmol SR 225 mg 12 Hour Capsule7.02USD capsule
Rythmol sr 225 mg capsule6.75USD capsule
Rythmol 225 mg tablet6.2USD tablet
Rythmol 300 mg tablet5.05USD tablet
Rythmol 150 mg tablet3.95USD tablet
Propafenone hcl 300 mg tablet3.03USD tablet
Propafenone hcl 225 mg tablet2.38USD tablet
Rythmol 300 mg Tablet2.09USD tablet
Propafenone hcl 150 mg tablet1.64USD tablet
Rythmol 150 mg Tablet1.18USD tablet
Apo-Propafenone 300 mg Tablet0.79USD tablet
Pms-Propafenone 300 mg Tablet0.79USD tablet
Apo-Propafenone 150 mg Tablet0.45USD tablet
Pms-Propafenone 150 mg Tablet0.45USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5681588No1994-10-282014-10-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00758 mg/mLALOGPS
logP3.1ALOGPS
logP3.54ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.63ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.56 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity100.21 m3·mol-1ChemAxon
Polarizability39.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier-0.958
Caco-2 permeable-0.5433
P-glycoprotein substrateSubstrate0.8548
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.874
Renal organic cation transporterNon-inhibitor0.7204
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5499
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.7066
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8931
Ames testNon AMES toxic0.8446
CarcinogenicityNon-carcinogens0.8879
BiodegradationNot ready biodegradable0.803
Rat acute toxicity2.3795 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5383
hERG inhibition (predictor II)Inhibitor0.8915
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as linear 1,3-diarylpropanoids. These are organic compounds with a structure based on a C6-C3-C6 skeleton, where the two benzene rings are not linked together.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Linear 1,3-diarylpropanoids
Sub Class
Not Available
Direct Parent
Linear 1,3-diarylpropanoids
Alternative Parents
Alkyl-phenylketones / Butyrophenones / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines
show 3 more
Substituents
Linear 1,3-diarylpropanoid / Alkyl-phenylketone / Butyrophenone / Phenylketone / Benzoyl / Phenol ether / Phenoxy compound / Aryl ketone / Aryl alkyl ketone / Alkyl aryl ether
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, secondary amino compound, aromatic ketone (CHEBI:63619)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Mergenthaler J, Haverkamp W, Huttenhofer A, Skryabin BV, Musshoff U, Borggrefe M, Speckmann EJ, Breithardt G, Madeja M: Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):472-80. [PubMed:11330342]
  2. Arias C, Gonzalez T, Moreno I, Caballero R, Delpon E, Tamargo J, Valenzuela C: Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Cardiovasc Res. 2003 Mar;57(3):660-9. [PubMed:12618228]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. McLeod AA, Stiles GL, Shand DG: Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther. 1984 Feb;228(2):461-6. [PubMed:6141285]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. McLeod AA, Stiles GL, Shand DG: Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther. 1984 Feb;228(2):461-6. [PubMed:6141285]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schmid D, Ecker G, Kopp S, Hitzler M, Chiba P: Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol. 1999 Nov 1;58(9):1447-56. [PubMed:10513988]
  2. Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF: Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2005 Mar;371(3):195-201. Epub 2005 Apr 15. [PubMed:15900513]
  3. Singh P, Paul K: Studies of interactions between uracil-based hybrid molecules and P-glycoprotein--search for multidrug resistance modulators. Bioorg Med Chem. 2006 Nov 1;14(21):7183-6. Epub 2006 Jul 14. [PubMed:16843673]
  4. Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther. 1997 Oct;283(1):39-45. [PubMed:9336306]
  5. Tmej C, Chiba P, Huber M, Richter E, Hitzler M, Schaper KJ, Ecker G: A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance. Arch Pharm (Weinheim). 1998 Jul-Aug;331(7-8):233-40. [PubMed:9747179]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:49